Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab deruxtecan vs Physician's Choice in HER2-low Advanced Breast Cancer
NCT03734029Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Dec 2018
- Primary completion
- Jan 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of trastuzumab deruxtecan in breast cancer, sponsored by Daiichi Sankyo Co., Ltd.. Started Dec 2018; status: completed.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03734029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03734029.